**MODIFIED PTO/SB/08 (08-00)** 

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCULAR Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known OIP **Application Number** INFORMATION DISCLOSURE 10/786,610 STATEMENT BY APPLICANT Filing Date 02/26/2004 SEP 2 9 2004 First Named Inventor Jingrong Jean CUI **Group Art Unit** 1644 1624 (use as many sheets as necessary) **Examiner Name** Unassigned Z.TVCK Sheet 2 **Attorney Docket Number** 034536-1148

				F	OREIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1	Office			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
ZT	B1	JP	07-109260	Α	FUJI PHOTO FILM CO LTD	04-25-1995		
ZT	B2	EP	0 204 285	B1	FUJISAWA PHARMACEUTICAL CO., LTD.	01-15-1992		
2	В3	EP .	1 044 967	B1	PFIZER INC. & PFIZER LIMITED	08-11-2004		
7	B4	wo	93/15055	A1	SMITHKLINE BEECHAM INTERCREDIT B.V.	08-05-1993		
25	B5 <sub>.</sub>	wo	99/55706	A1	ASTRA AKTIEBOLAG	11-04-1999		
27	B6	wo	01/00213	A1	MERCK & CO., INC.	01-04-2001		
2.7	В7	wo	01/60806	A2	NEUROGEN CORPORATION	08-23-2001		
マナ	B8	wo	02/056882	A1	SMITHKLINE BEECHAM P.L.C.	07-25-2002		
子	B9	wo	03/000666	A1	PFIZER PRODUCTS INC.	01-03-2003		
27	B10	wo	03/045924	A1	PHARMACIA & UPJOHN COMPANY	06-05-2003		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>					
ंद	B11	BRADBURY et al., "New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure – Activity Relationships of 5-(Dimethylamino)- <i>N</i> -pyridyl-, - <i>N</i> -pyrimidinyl-, - <i>N</i> -pyridazinyl-, and – <i>N</i> -pyrazinyl-1-naphthalenesulfonamides," <u>J. Med. Chem.</u> , 1997, pp. 996-1004, Vol. 40, No. 6						
37	B12	BRISTOL et al., "An Improved Synthesis of 2-Amino-3-alkyloxypyridines by a Phase-Transfer Catalyzed Ether Synthesis," Synthesis, December 1981, pp. 971-973, Vol. 12						

Examiner Signature	Zalh_	Date Considered	25 JANVARY 2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	form 1449B	/PTO	Complete if Known		
	INFORMATIO	N DISCLO	SURE	Application Number	10/786,610	
	STATEMENT BY APPLICANT			Filing Date	02/26/2004	
				First Named Inventor	Jingrong Jean CUI	
				Group Art Unit	1644-1624	
	(use as many s	heets as ne	cessary)	Examiner Name	-Unaccigned 2. TVCKER	
Sheet	2	of	2	Attorney Docket Number	034536-1148	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>®</sup>
3	B13	DENNIN, et al., "Synthesis of Derivatives of Pyrazino[1,2-a]pyrimindin-4-ones," <u>Journal of Heterocyclic</u> <u>Chemistry</u> , September-October 1990, pp. 1639-1643, Vol. 27	
37	B14	FOKS et al., "Studies on Pyrazine Derivatives. XXX. Sythesis of Pyrazinylamino-1,3-Diazacycloalkanes of Potential Circulatory Activity," <u>Acta Poloniae Pharmaceutica</u> , January/February 1997, pp. 55-62, Vol. 54, No. 1	
3	B15	KAMINSKI et al., "Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[1,2-a]pyridines and Analogues," <u>J. Med. Chem.</u> , 1987, pp. 2031-2046, Vol. 30	
ZT	B16	SHIMOMURA et al., "Semi-synthetic aequorins with improved sensitivity to Ca <sup>2+</sup> ions," <u>Biochem. J.,</u> 1989, pp. 913-920, Vol. 261	
27	B17	SOLLOGOUB et al., "First synthesis of 1-deazacytidine, the C-nucleoside analogue of cytidine," Tetrahedron Letters, 2001, pp. 3121-3123, Vol. 43	
र्स	B18	WISTEROWICZ et al., Acta Poloniae Pharmaceutica, 1997, pp. 55-62, Vol. 54, No.1	
		,	

_				
	xaminer Signature	Talh	Date Considered	25 JANUARY 2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

**MODIFIED PTO/SB/08 (08-00)** 

DUPLICATE

CITATION

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.							2.6	
	Substitute f	or form 1449B	/PTO	<u> </u>	Complete if Known	70.	4	
	INFORMATI	ION DISCLO	SURE	Application Number	10/786,610	1		:/
	STATEMEN	IT BY APPLI	ICANT	Filing Date	02/26/2004	SEP 0	1 2004	w.
ŀ				First Named Inventor	Jingrong Jean CUI	2	Š	₹/
				Group Art Unit	1644 1624	12	0	7
	(use as many	sheets as ne	ecessary)	Examiner Name	Unassigned Z.TV	CKERS & TR	DEMAR	
Sheet	1	of	1	Attorney Docket Number				

				U.S. PATENT DOCUMENTS			
		U.S. Patent I	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Kind Number Code <sup>2</sup> (if known)		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
			-				
			<del></del>				
				,	,		

					FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Office <sup>3</sup>	oreign Patent D Number <sup>4</sup>	Ocument Kind Cod (if known		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
-	<del>A1</del>	wo	03/00066		<del>A1</del> -	PFIZER PRODUCTS INC.	01-30-2003		
	-								T
									1

DUPLICATE

CETATION

NON PATENT LITERATURE DOCUMENTS								
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т					
		·						
			+					

Examiner Signature	Alh	Date Considered	25 JANUARY 2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.